16106 Background: Incidental prostate cancer (CaP) presents a highly different risk of progression for T1a and T1b disease (T1a: 10–26% at 7–10 years; T1b: up to 30 % at 2 years), even in more recent series. An incorrect definition of stage can strongly impact on patient’s survival, so we restaged our patients after transurethral resection of the prostate (TURP) by means of a second procedure, consisting of a repeated TURP plus ultrasound-guided biopsies (BxP). The study investigated prospectively these two diagnostic modalities with the aim to discover which one provides the best detection rate. Methods: Between January 1997 through January 2006, 50 T1a CaP were discovered in patients submitted to TURP (1021pts). Median prostate-specific antigen (PSA) before the operation was 5.25 ng/ml (range 0.6 - 17). After three months, prior PSA reevaluation, all patients underwent a second resection in conjunction with an ultrasound-guided transrectal biopsy (six cores). Results: After the first TURP median PSA was 1.35 ng/ml (range 0 - 4.02). Residual disease was demonstrated in 20 patients (40%) [median PSA 1.19 (range 0.4 - 4.02)], then treated surgically or not, depending on age or comorbidities. Among them, in 7 cases (14%) both re- TURP and BxP were positive; in 7 patients (14%) repeated TURP was positive and BxP negative (p n.s.), while in the remaining 6 (12%) repeated TURP was negative and BxP positive (p n.s.). Twelve out of 20 patients (median age 68) with persistent cancer underwent radical surgery and locally advanced disease was revealed in 3 (25%), with one patient having a Gleason score 9. Conclusions: In these series 40% of patients, initially diagnosed in stage T1a, revealed residual tumor after restaging. This high percentage warranted the discomfort and the costs of a second procedure. Either repeated TURP and BxP failed to demonstrate an advantage over each other in terms of “detection rate”. A 10% false negative rate for both prompts us to associate the two modalities instead of choosing between them, in order to discover a potentially lethal residual disease for which, in many cases, a definitive treatment is to be considered. No significant financial relationships to disclose.